THE US Food and Drug Administration has approved Gilenya (fingolimod) for the treatment of relapsing multiple sclerosis (MS) in children and adolescents aged 10 years & over.
It's the first FDA approval of a drug to treat MS in child patients.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 May 18